The head of Daiichi Sankyo, the Japanese pharmaceutical company, expressed his regrets over the high cost of the purchase last year of Ranbaxy, the Indian generic drugs group, while defending the future benefits of the deal.

Takashi Shoda told the Financial Times: “We take the responsibility and we feel very apologetic to the shareholders for having damaged their equity. But in the medium to long term I am still very confident about the potential.”